Which sequence correctly describes the preclinical progression?

Which sequence correctly describes the preclinical progression?

• A. Firstly cells, then tissues, then live animals
• B. Live animals, then tissues, then cells
• C. Tissues, then cells, then live animals
• D. Humans first

Answer: (A)

In preclinical development, the testing sequence moves from simple to more complex biological systems. You start with experiments on isolated cells to learn basic effects, mechanisms, and safety at the smallest, least complex level. This helps identify dose ranges and potential cytotoxicity without the confounding factors of whole tissues or organisms. Next, you study tissues or tissue-like systems to see how cells interact in a more realistic environment, capturing how different cell types and the extracellular matrix influence responses. Finally, you test in a living organism to understand how the system behaves as a whole—the integrated pharmacokinetics, distribution, metabolism, and systemic safety that can’t be captured in cell or tissue models alone. This progression—from cells to tissues to live animals—best describes the preclinical path. Starting with living animals or with humans first would skip essential early steps and introduce more complexity and risk at the outset.

In preclinical development, the testing sequence moves from simple to more complex biological systems. You start with experiments on isolated cells to learn basic effects, mechanisms, and safety at the smallest, least complex level. This helps identify dose ranges and potential cytotoxicity without the confounding factors of whole tissues or organisms. Next, you study tissues or tissue-like systems to see how cells interact in a more realistic environment, capturing how different cell types and the extracellular matrix influence responses. Finally, you test in a living organism to understand how the system behaves as a whole—the integrated pharmacokinetics, distribution, metabolism, and systemic safety that can’t be captured in cell or tissue models alone. This progression—from cells to tissues to live animals—best describes the preclinical path. Starting with living animals or with humans first would skip essential early steps and introduce more complexity and risk at the outset.